CN1193753C - Ginkgo leaf extract and injection fluid containing same - Google Patents
Ginkgo leaf extract and injection fluid containing same Download PDFInfo
- Publication number
- CN1193753C CN1193753C CN 03150054 CN03150054A CN1193753C CN 1193753 C CN1193753 C CN 1193753C CN 03150054 CN03150054 CN 03150054 CN 03150054 A CN03150054 A CN 03150054A CN 1193753 C CN1193753 C CN 1193753C
- Authority
- CN
- China
- Prior art keywords
- extract
- ethanol
- injection
- liquor
- filtrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to ginkgo leaf extract. The extract is prepared by the following method that fresh ginkgo leaves are cleaned and pulped; thick slurry is extracted by ethanol; the pH valve of the alcohol extracted liquor is adjusted with a range of 8 to 10 by alkali; the obtained liquor is filtered; the pH valve of the filtered liquor is adjusted within a range of 3 to 8 by acid; the preferable pH valve is within a range of 5 to 6; the obtained liquor is filtered; the ethanol is recovered from the filtered liquor; black brown dope is obtained; hot water is added for extraction; aqueous extract liquor is stored in a cooling mode and is filtered; a macroporous resin column in filtered liquor is used for desalting; gradient ethanol is eluted; the ethanol is recovered; the content of total falconoids in concentrated extracted liquor of ginkgo leaves is optionally detected. The present invention also relates to ginkgo leaf injection; the preparation comprises that the extract products are further prepared into injection. The contents of the effective components such as total flavonoids, ginkalide, etc., of the injection of the ginkgo leaf extract of the present invention are high; a therapeutic effect is excellent.
Description
Invention field
The present invention relates to a kind of total flavones, Folium Ginkgo extract that the bilobalide equal size is high, and contain its injection, be called SHUXUENING ZHUSHEYE again.
Background technology
YINXINGYE ZHUSHEYE has been used for many years in clinical treatment, blood vessel dilating, microcirculation improvement and hemorheology, removing free radical, the infringement etc. that alleviates nuisance all there is good effect, relevant on the market gingko leaf preparation kind is a lot, as, YINXINGYE ZHUSHEYE, Tian Bao sheet etc.
Folium Ginkgo total flavones, bilobalide effective component content when late September to early October is the highest, and this moment, extract yield was also the highest.Total flavones, bilobalide effective component content then have decline in various degree in the dried blade, and the long more content of waiting time descends many more.
Existing extraction process all is to adopt dry Folium Ginkgo to extract, and the organic solvent that extraction process is used is many, and as ethanol, acetone, cost is higher, technical sophistication.
In view of this, the bright Folium Ginkgo after the present invention proposes a kind of utilization and gathers, high efficiency extraction total flavones and bilobalide active ingredient are also made the method for YINXINGYE ZHUSHEYE.
Summary of the invention
The fresh gingko leaf that the present invention adopts extracts.In general, with dry Folium Ginkgo extraction then, general flavone content can only reach 6%, reduces to 4% with the dry Folium Ginkgo extraction general flavone content of next year.And adopt method of the present invention, and extracting with the fresh gingko leaf, total flavones, bilobalide, bilobalide can both meet international standards: total flavones reaches 22～26%, and bilobalide reaches 2.5～4.5%, and bilobalide reaches 2～4%.And technology of the present invention is simple, and consumption of organic solvent is also less.
Therefore, the purpose of this invention is to provide a kind of Folium Ginkgo extract, this extract prepares by the following method:
Bright Folium Ginkgo cleans making beating, stiff serosity ethanol extraction, alcohol extract adjusting PH with base 8-10, filter, filtrate is transferred pH3-8 with acid, preferred 5-6, filter, filtrate recycling ethanol obtains dark brown dope, hot water extraction, the cold preservation of water extract is filtered, macroporous resin column desalination on the filtrate, gradient ethanol elution, reclaim ethanol, optional dense ginkgo biloba succi total flavones and the bilobalide content of detecting.
Wherein, generally comprise with 3-8 with ethanol extraction and doubly to measure 50-95%, preferred about 70% ethanol and optional small amount of antioxidant reflux, extract, 2-5 hour are extracted 2-5 time altogether.Transferring the alkali of pH can be calcium hydroxide, sodium bicarbonate, and sodium carbonate, potassium carbonate etc., transferring the acid of pH for example can be hydrochloric acid, acetic acid, sulphuric acid etc.
The temperature of hot water for example can be 60 ℃ to 100 ℃ in the hot water extraction, also can be higher.
The temperature of cold preservation is generally-30 ℃ to 5 ℃, and preferred-5 to 5 ℃ approximately, more preferably from about 0 ℃.Cold preservation time for example can be 2 minutes to 72 hours, preferably about 1-20 hour.
Another object of the present invention provides the preparation method of YINXINGYE ZHUSHEYE, and this method comprises following operation:
Bright Folium Ginkgo cleans making beating, stiff serosity ethanol extraction, alcohol extract adjusting PH with base 8-10, filter, filtrate is transferred pH3-8 with acid, preferred 5-6, filter, filtrate recycling ethanol obtains dark brown dope, hot water extraction, the cold preservation of water extract is filtered, macroporous resin column desalination on the filtrate, the gradient ethanol elution, reclaim ethanol, optional dense ginkgo biloba succi total flavones and the bilobalide content of detecting obtains Folium Ginkgo extract;
The said extracted thing is made injection with water for injection, and concentration makes and is equivalent to crude drug 0.5-5g/ml injection.
Wherein, generally comprise with 3-8 with ethanol extraction and doubly to measure 50-95%, preferred about 70% ethanol and optional small amount of antioxidant reflux, extract, 2-5 hour are extracted 2-5 time altogether.Transferring the alkali of pH can be calcium hydroxide, sodium bicarbonate, and sodium carbonate, potassium carbonate etc., transferring the acid of pH for example can be hydrochloric acid, acetic acid, sulphuric acid etc.
The temperature of hot water for example can be 60 ℃ to 100 ℃ in the hot water extraction, also can be higher.
The temperature of cold preservation is generally-30 ℃ to 5 ℃, and preferred-5 to 5 ℃ approximately, more preferably from about 0 ℃.Cold preservation time for example can be 2 minutes to 72 hours, preferably about 1-20 hour.
In a preferred embodiment, the invention provides Semen Ginkgo extrac, it is characterized in that by following method preparation:
Use band beater pulping after getting bright Folium Ginkgo clean dry, add 3-8 and doubly measure 60-95%, preferred about 70% ethanol and the antioxidant 0.001-2wt% of bright ginkgo biloba leaf total weight (for example based on) reflux, extract, 2-5 hour, extract 2-5 time altogether, merge in the alcohol extract adding aqueous alkali and transfer PH8-10, left standstill 2-6 hour, filter, reuse acid, preferred hydrochloric acid readjustment PH3-8, decompression recycling ethanol gets dark brown dope, adds 3-8 times of calorimetric distilled water and stirs evenly and boil 10-25 minute, 20-40 minute after-filtration, twice merging filtrate of filtering residue reheat decocting in water, cold preservation elimination insoluble matter once more that spends the night, macroporous resin column is with distilled water flush away salinity on the filtrate, reuse gradient ethanol from low concentration to the high concentration eluting, collect 30%-80% ethanol elution part, recovery ethanol gets dense ginkgo biloba succi to there not being the alcohol flavor, optional detection level obtains ginkgo biloba succi.
In another preferred embodiment, the invention provides YINXINGYE ZHUSHEYE, it is characterized in that by following method preparation:
The preparation of ginkgo biloba succi: use band beater pulping after getting bright Folium Ginkgo clean dry, add 3-8 and doubly measure 60-95%, preferred about 70% ethanol and the small amount of antioxidant 0.001-2wt% of bright ginkgo biloba leaf total weight (for example based on) reflux, extract, 2-5 hour, extract 2-5 time altogether, merge in the alcohol extract adding aqueous alkali and transfer PH8-10, left standstill 2-6 hour, filter, reuse acid, preferred hydrochloric acid readjustment PH3-8, decompression recycling ethanol gets dark brown dope, adds 3-8 times of calorimetric distilled water and stirs evenly and boil 10-25 minute, 20-40 minute after-filtration, twice merging filtrate of filtering residue reheat decocting in water, cold preservation elimination insoluble matter once more that spends the night, macroporous resin column is with distilled water flush away salinity on the filtrate, reuse gradient ethanol from low concentration to the high concentration eluting, collect 30%-80% ethanol elution part, recovery ethanol gets dense ginkgo biloba succi to there not being the alcohol flavor, optional detection level obtains ginkgo biloba succi;
The dense ginkgo biloba succi of getting the step is an amount of, and the amount of supplying water for injection (is equivalent to 0.5g-5g crude drug/ml) and adds 0.05-0.25% needle-use activated carbon, 0.02%-0.06% antioxidant, for example NaHSO
3, 0.02%-0.06%EDTA-Na
2Boil filtration in 5-25 minute, filtrate is after supermicro filtration membrane (for example the molecular retention amount is 10,000 supermicro filtration membrane), the different size injection is made in fill as required respectively, and sterilization (for example 100 ℃ sterilization 15-30 minute) promptly get the YINXINGYE ZHUSHEYE finished product that can supply intramuscular injection or quiet behind the sealing by fusing.
Extraction principle of the present invention and technical essential are:
Extract whole process and can not meet ferrum, otherwise the flavone blackening.
Antioxidant is NaHSO for example
3, ascorbic acid etc. avoid flavone to be subjected to heat damage to reduce yield.
Contain impurity such as a large amount of chlorophylls and tannin in the bright leaf, in alkaline ethanol, can produce precipitation and get rid of.But alkalescence is too high is the total flavones parent nucleus to be destroyed so to be controlled at PH10 be good.
When pulling back to PH5.5 with HCL flavone stablize heat-resisting be beneficial to refining.
Macroporous resin selects the D-101 type, can adsorb total flavones well, and CaCl
2Be not adsorbed Deng salinity and wash out with moisture.
30% ethanol can wash out invalid components such as bisflavone.
EDTA-Na2 (ethylenediaminetetraacetic acid one disodium) can prevent that trace metal ion from urging the total flavones oxidation, thereby makes injection stable.
Embodiment
Further specify the present invention by the following examples, it should be understood that these embodiment only are used for explanation, do not constitute limitation of the scope of the invention.
Embodiment 1
Get bright Folium Ginkgo 1000g, be ground into paste, add ethanol and the 1gNaHSO of 5000ml 70% with beater
3Reflux, extract, 3 hours, filter again the same extraction of filtering residue is filtered for 2 times, merge 3 filtrates and add saturated limewater accent PH10, produce dirty green precipitate, leave standstill more than 4 hours, filter, add hydrochloric acid and transfer PH5.5, decompression recycling ethanol obtains the about 300g of dark brown dope, adding the 1500ml hot distilled water boiled 15 minutes, filter, filtering residue extract equally the more yellow water extract of twice merging 0 ℃ of cold preservation spend the night filter on the back macroporous resin column (can adsorb fully) control with the 800g resin drip speed to current to the greatest extent back elder generation wash impurity with 30% ethanol, to effluent colourless after, again with 50% ethanol elution to effluent colourless till, to 50% ethanol elution reclaim ethanol to do not have alcohol distinguish the flavor of the about 450ml of dense ginkgo biloba succi, detection level gets final product.
Embodiment 2
Get bright Folium Ginkgo 1000g, be ground into paste, add ethanol and the 1gNaHSO of 5000ml 70% with beater
3Reflux, extract, 3 hours, filter again the same extraction of filtering residue is filtered for 2 times, merge 3 filtrates and add saturated limewater accent PH10, produce dirty green precipitate, leave standstill more than 4 hours, filter, add hydrochloric acid and transfer PH5.5, decompression recycling ethanol obtains the about 300g of dark brown dope, adding the 1500ml hot distilled water boiled 15 minutes, filter, filtering residue extract equally the more yellow water extract of twice merging 0 ℃ of cold preservation spend the night filter on the back macroporous resin column (can adsorb fully) control with the 800g resin drip speed to current to the greatest extent back elder generation wash impurity with 30% ethanol, to effluent colourless after, again with 50% ethanol elution to effluent colourless till, to 50% ethanol elution reclaim ethanol to do not have alcohol distinguish the flavor of the about 450ml of dense ginkgo biloba succi, detection level, standby.
To go up the dense ginkgo biloba succi of step gained adds injection water 600ml and adds 1g needle-use activated carbon and 0.4gNaHSO
3, 0.4gEDTA-Na
2Boiled 15 minutes, filtered while hot, reuse supermicro filtration membrane fine straining, fill sealing by fusing (2ml/ props up) makes the YINXINGYE ZHUSHEYE finished product in 100 ℃ of sterilizations 15 minutes under the inflated with nitrogen condition, keeps in Dark Place.
Test one, the clinical trial of YINXINGYE ZHUSHEYE of the present invention treatment cerebral infarction
SHUXUENING ZHUSHEYE of the present invention is a ginkgo leaf extract preparation.Wherein mainly be divided into total flavones alcohol glycoside, Semen Ginkgo lactone.Its effective ingredient can be regulated antiotasis, improves internal organs blood circulation and tip microcirculation.Ginkalide B has very strong paf receptor blocking effect, suppress the PAF activity, reduce whole blood viscosity, plasma viscosity and plasma fibrinogen, improve blood flowing characteristic, reduce microthrombusis, and it is a stronger free radical scavenger, stronger antioxidation is arranged and remove the free radical effect.My institute has carried out the Comparison of therapeutic analysis to the 96 routine acute cerebral infarction patients that are admitted to hospital.
Case is selected: this observation case is an inpatient, and selected patient all meets the 4th the cerebrovascular meeting revised standard in the nineteen ninety-five whole nation, and confirms through brain CT or brain MRI.Neurological deficits score adopts European standards of grading before and after the patient.50 examples are organized in treatment, heavy 20 examples, medium-sized 18 examples, light-duty 12 examples: matched group 46 examples, heavy 21 examples, medium-sized 16 examples, light-duty 9 examples.Treatment group infarction position: Basal ganglia 24 examples, corona radiata 10 examples, brain stem 2 examples, cerebral lobe 4 examples, thalamus 5 examples, multiple chamber obstruct 5 examples; Matched group infarction position: Basal ganglia 22 examples, corona radiata 8 examples, brain stem 1 example, cerebral lobe 6 examples, thalamus 3 examples, multiple chamber obstruct 6 examples.
Therapeutic Method: treatment group SHUXUENING ZHUSHEYE (per 2 milliliters contain 1.68 milligrams of total flavones alcohol glycosides, contain Semen Ginkgo lactone A0.12 milligram) adds 250 milliliters of intravenous drips of 5% Dextrose and Sodium Chloride Inj. for 20 milliliters, qd, and 14 days is a course of treatment; The brain polypeptide injection adds 250 milliliters of intravenous drips of 5% Dextrose and Sodium Chloride Inj. for 20 milliliters, qd, and 14 days is a course of treatment; 10 milligrams of Ao Libaoke, qd, po, 30 days is a course of treatment.The matched group XUESAITONG ZHUSHEYE adds 250 milliliters of intravenous drips of 5% Dextrose and Sodium Chloride Inj. for 8 milliliters, qd, and 14 days is a course of treatment; Brain polypeptide, Ao Libaoke usage are the same.Two groups of patients need add with treatments such as mannitol according to the state of an illness, and two groups of patients adopt venous blood respectively before and after treatment, carry out hemorheology and learn inspection.
Efficacy determination: 1, be almost recovered: clinical symptoms and sign disappear substantially.2, produce effects: paralyzed limbs Myodynamia recovery to 4 is to 5 grades, and aphasis partly recovers.3, effective: the paralyzed limbs muscular strength is more than 2 grades, and aphasis partly recovers.4, invalid: clinical symptoms and sign no change.5, worsen: the state of an illness increases the weight of.
The result
1, clinical efficacy:
Table 1, two groups of patients clinical curative effects are relatively
| Group | The example number | Be almost recovered | Produce effects | Effectively | Invalid | Worsen | |
| The treatment group | 50 | 8 | 18 | 20 | 3 | 1 | |
| Matched group | 46 | 4 | 16 | 18 | 5 | 3 |
2, hemorheology changes:
Table 2: two groups of patient blood rheologys change
| Project | Before the treatment | After the treatment | |
| The treatment group | Whole blood contrast viscosity | ||
| The low specific viscosity of cutting of whole blood | 7.68±1.92 | 6.56±1.01 | |
| The whole blood height is cut specific viscosity | 5.51±3.01 | 4.92±2.66 | |
| Plasma viscosity | 1.53±0.18 | 1.21±0.21 | |
| Fibrinogen | 4.32±1.38 | 3.24±1.25 | |
| Matched group | Whole blood contrast viscosity | ||
| The low specific viscosity of cutting of whole blood | 7.81±1.86 | 7.02±0.87 | |
| The whole blood height is cut specific viscosity | 6.01±2.9 | 5.82±2.4 | |
| Plasma viscosity | 1.4±60.20 | 1.3±80.17 | |
| Fibrinogen | 4.27±1.26 | 4.0±11.18 | |
After above-mentioned data are learned processing by statistics, P＜0.05
Two groups of obvious effective rates are respectively 85% and 56%, the neurological deficits score two groups of relatively treatment group better effects if (p＜0.05) that reduce that obviously there were significant differences (p＜0.05) between (p＜0.001) two groups of treatments bleeding from anus rheology index before and after treatment group and the treatment of control group, conclusion: it is better that SHUXUENING ZHUSHEYE of the present invention adds require mental skill cell activator and calcium ion antagonist treatment cerebral infarction effect.
This data shows that SHUXUENING ZHUSHEYE of the present invention is a kind of strong free radical scavenger, stronger antioxidation is arranged and remove the free radical effect, can alleviate cerebral edema, the hardened generation of prevention of arterial, all right antiplatelet aggregation, reduce plasma fibrinogen, suppress the formation of thrombosis, cerebral blood flow increasing, can make the patient reaction realize quickening, memory improvement, improve the cerebral oxygen supply state, promote the brain metabolism, by observing obvious, rapid, the safety of proof SHUXUENING ZHUSHEYE treatment cerebral infarction curative effect, be worthy to be popularized.
Test two, injection for treating acute cerebral infarction effect assessment of the present invention
Data and method
1, object of study acute cerebral infarction patient " all kinds of diagnosis and treatment of cerebrovascular diseases main points " passed through by the 4th the cerebrovascular academic conference in the nineteen ninety-five whole nation, and Patients with Cerebral Infarction 60 examples that confirm through head CT or MRI, be divided into SHUXUENING treatment group of the present invention and troxerutin matched group at random with throwing the coin method, male 18 examples are organized in treatment, women 12 examples, age 37-75 year, average 62.4 years old, its medium and heavy patient's 3 examples, medium-sized patient's 19 examples, light-duty patient's 8 examples; Matched group man 19 examples, women 11 examples, age 41-74 year, average 61.5 years old; Its medium and heavy 3 examples, medium-sized 17 examples, light-duty 10 examples, two groups of patients all do not have marked difference in age, sex, neurological deficits score, merging disease and complication through X 2 test.
2, Therapeutic Method treatment group is with quiet of SHUXUENING ZHUSHEYE 10ml+10% glucose 200ml+ insulin 4u of the present invention every day 1 time, and 14 is 1 course of treatment.Matched group is all used quiet 1 course of treatment on the 14th of Biot's star 15ml+ normal saline 200ml for two groups simultaneously with troxerutin 1g+10% glucose 200ml+ insulin 4u, need add according to the state of an illness and use the mannitol dehydration therapy.Before treatment and adopt venous blood after 14 days respectively and detect NO, ET, SOD and MDA, carry out neurological deficits score and ADL scoring after all around.
3, the whole patients of lab testing adopt fasting blood the be admitted to hospital same day and second day early morning, the NO nitrate reductase method, ET radio immunoassay, SOD pyrogallol autoxidation enzyme process, MDA operates with sulfo-barbital TBA method, equal ammonium description method practicing engineer strictness.
4, the 4th national cerebrovascular meeting standards of grading of efficacy determination reference: be almost recovered: functional impairment reduces 90-100%, and invalid degree is 0 grade; Marked improvement: functional impairment reduces 46-90%, and invalid degree is the 1-3 level; Progressive: functional impairment reduces 18-45%; No change: functional impairment reduces or increases by 17%; Worsen: the functional impairment scoring increases by 18% or dead.Total effective rate is for being almost recovered+marked improvement+progress.ADL scale: produce effects: treatment back scale integration descends 〉=2/3; Effectively: integration decline 1/3-2/3; Invalid: integration descends not enough in 1/3.
5, the equal software kit SPSS1.0 analyzing and processing by statistics of statistical procedures Data Processing in Experiment.Method adopts t check and x2 check.
The result
1, laboratory result sees Table 1 before and after injection of the present invention and the treatment of control group.
2, neurological deficits score sees Table 2 before and after injection of the present invention and the treatment of control group.
3, injection of the present invention relatively sees Table 3 with contrast treatment front and back ADL integration.
Lab testing comparison before and after table 1 injection of the present invention and the treatment of control group (x ± s)
| Group | NO | ET | SOD | MDA |
| Before the treatment | After the treatment | Before the treatment | After the treatment | Before the treatment | After the treatment | Before the treatment | After the treatment | |
| The present invention | 59.03±1 1.81 | 36.23±1 4.17 ** ▲ | 88.48±1 5.89 | 66.34± 9.58 *▲ | 49.91±1 2.34 | 62.58± 18.32 * ▲ | 4.59± 1.23 | 4.19±1 .03 |
| Matched group | 54.34±9 .18 | 40.41±5 .66 * | 90.85±1 8.21 | 84.62± 16.23 | 47.65±1 8.23 | 49.23± 15.61 | 4.38± 1.02 | 4.29±1 .11 |
Compare with matched group:
*P＜0.05
*P＜0.01, comparison ▲ p＜0.05 before and after the treatment
Table 2
Neurological deficits score comparison before and after two groups of treatments (X ± S)
| Group | The example number | Before the treatment | After the treatment |
| The present invention | 30 | 36.5±4.8 | 12.85±3.3 **▲ |
| Matched group | 30 | 34.9±6.5 | 24.64±5.7 * |
Compare with matched group:
*P＜0.05
*P＜0.01, compare before and after the treatment ▲ ▲ p＜0.01
ADL scoring (X ± S) relatively before and after the treatment of table 3 liang group
| Group | The example number | Produce effects | Effectively | Invalid | Total effective rate |
| The present invention | 30 | 11 | 14 | 5 | 83.33▲ |
| Matched group | 30 | 6 | 13 | 11 | 63.33 |
▲ compare p＜0.01 with matched group
Discuss: the pathophysiological mechanism complexity of acute cerebral infarction, relevant with multiple paathogenic factor, wherein NO, ET are regional flow's regulatory factors, its dynamic equilibrium has substantial connection to keeping cerebrovascular shrink function, behind cerebral infarction because the cerebral tissue hypoxic-ischemic, ET is increased, produce InsP3, cause Ca then by ET-A receptor activation phospho-esterase c
2+Interior stream, and produce free radical, NO then has neural poison and neuroprotective dual function when cerebral ischemia.The NO of research prompting at present is created in first few and hour has neuroprotective.NO rises rapidly behind cerebral infarction, peaks in 24 hours, and the NO that early produces in the issue minute at cerebral infarction is favourable, but the NO that produces in a couple of days after a few hours is then toxic to nerve.Behind the cerebral infarction since blood vessel endothelial factor excited a large amount of free-radical generating unusually, considerably beyond the removing ability of body, cause free radical to pile up and lipid peroxidation, form lipid peroxide.MDA is that oxygen-derived free radicals is attacked the metabolic end product that lipid causes peroxide, and its content has reflected the generation level of oxygen-derived free radicals in the body and to the brain tissue injury degree.SOD can generate H by the super oxygen silver ion of catalysis
2O
2And O
2, SOD can protect cerebral tissue, is the leading indicator of removing oxygen-derived free radicals.This result of study prompting injection of the present invention can reduce the toxic action of NO and ET, improves SOD content, thereby effective antagonism peroxide injury is removed free radical, protects brain cell and reduces apoptosis.Ginkalide B has very strong paf receptor blocking effect in addition, suppress the PAF activity, reduce whole blood viscosity, plasma viscosity and fibronectin, reduce thrombosis and microcirculation improvement, can effectively treat cerebral infarction and not have obvious toxic-side effects, be the good medicine that has much application prospect of treatment and prophylaxis of acute cerebral infarction.
Claims (8)
1, a kind of Folium Ginkgo extract, this extract prepares by the following method:
Bright Folium Ginkgo cleans making beating, stiff serosity ethanol extraction, alcohol extract adjusting PH with base 8-10, filter, filtrate is transferred pH3-8 with acid, filters, filtrate recycling ethanol, obtain dark brown dope, hot water extraction, the cold preservation of water extract is filtered, macroporous resin column desalination on the filtrate, the gradient ethanol elution reclaims ethanol, optional dense ginkgo biloba succi general flavone content and the bilobalide content of detecting.
2, according to the Folium Ginkgo extract of claim 1, it is characterized in that: comprise that with ethanol extraction doubly measuring 50-95% ethanol with 3-8 reaches optional small amount of antioxidant reflux, extract, 2-5 hour, extracts 2-5 time altogether; With alcohol extract with the adjusting PH with base value and after filtering, again with gained filtrate with sour adjust pH to 5-6;
3, according to the Folium Ginkgo extract of claim 1, it is characterized in that: wherein the temperature of cold preservation is-30 ℃ to 5 ℃, and cold preservation time is 2 minutes to 72 hours.
4, according to the Folium Ginkgo extract of claim 3, it is characterized in that: wherein the temperature of cold preservation is-5 to 5 ℃, and cold preservation time is 1-20 hour.
5, according to the Folium Ginkgo extract of claim 3, it is characterized in that: wherein the temperature of cold preservation is 0 ℃.
6, according to the Folium Ginkgo extract of claim 1, it is characterized in that: 3-8 times of calorimetric distilled water of adding in the dark brown dope of gained stirred evenly boil 10-25 minute, 20-40 minute after-filtration, twice merging filtrate of filtering residue reheat decocting in water, the cold preservation elimination insoluble matter once more that spends the night, on the filtrate macroporous resin column with distilled water flush away salinity, reuse gradient ethanol from low concentration to the high concentration eluting, collect 30%-80% ethanol elution part, reclaim ethanol to there not being the alcohol flavor.
7, YINXINGYE ZHUSHEYE, this injection is prepared by following method:
Arbitrary product of claim 1-6 is made injection promptly with water for injection.
8,, it is characterized in that by following method preparation according to the YINXINGYE ZHUSHEYE of claim 7:
The weighting profit requires arbitrary product of 1-6, and the amount of supplying water for injection is equivalent to 0.5g-5g crude drug/ml, and adds the 0.05-0.25% needle-use activated carbon, the NaHSO of 0.02%-0.06%
3, 0.02%-0.06% EDTA-Na
2Boil filtration in 5-25 minute, filtrate is 10,000 supermicro filtration membrane after the molecular retention amount, and the different size injection is made in fill as required respectively, and 100 ℃ of sterilizations sterilization in 15-30 minute promptly get the YINXINGYE ZHUSHEYE finished product that can supply intramuscular injection or quiet behind the sealing by fusing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03150054 CN1193753C (en) | 2003-07-31 | 2003-07-31 | Ginkgo leaf extract and injection fluid containing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03150054 CN1193753C (en) | 2003-07-31 | 2003-07-31 | Ginkgo leaf extract and injection fluid containing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1481793A CN1481793A (en) | 2004-03-17 |
| CN1193753C true CN1193753C (en) | 2005-03-23 |
Family
ID=34156419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03150054 Expired - Lifetime CN1193753C (en) | 2003-07-31 | 2003-07-31 | Ginkgo leaf extract and injection fluid containing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1193753C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100496518C (en) | 2005-07-18 | 2009-06-10 | 厦门国宇知识产权研究有限公司 | Ginkgo leaf extract, injection containing said extract and its preparing method |
| CN1813782B (en) * | 2005-12-02 | 2010-09-22 | 厦门国宇知识产权研究有限公司 | Composition of ginkgo leaf extract and dipyridamole, medicine containing same and preparing method thereof |
| CN100469774C (en) * | 2006-04-13 | 2009-03-18 | 厦门国宇知识产权研究有限公司 | Ginkgo leaf extract and production process of separating high purity effective component of the extract |
| CN106166164B (en) * | 2016-07-29 | 2020-01-10 | 湖南绿蔓生物科技股份有限公司 | Preparation method of ginkgo leaf extract and product thereof |
| CN106434185A (en) * | 2016-12-23 | 2017-02-22 | 成都景睿生物科技有限公司 | Healthcare wine preparation method |
| CN113774711B (en) * | 2021-10-07 | 2022-07-22 | 华南理工大学 | Pineapple whole-leaf antibacterial powder coating and preparation method thereof |
-
2003
- 2003-07-31 CN CN 03150054 patent/CN1193753C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1481793A (en) | 2004-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102283870B (en) | High-purity folium ginkgo composition, preparation including same and preparation method thereof | |
| CN101412703A (en) | Composite extracting technique for coproduction of mulberry tea flavone, polysaccharide and alkaloid | |
| CN105193876B (en) | Purslane extract and preparation method thereof | |
| CN1193753C (en) | Ginkgo leaf extract and injection fluid containing same | |
| CN113350234A (en) | Preparation method and application of allergy-relieving repair compound | |
| CN114832022B (en) | Preparation of Phellinus linteus fruiting body phenol active substances and application thereof in regulating intestinal flora and uric acid metabolism | |
| CN110859785A (en) | Preparation method and application of anti-allergy compound | |
| CN105418785B (en) | A kind of production method of Radix Et Caulis Acanthopanacis Senticosi polysaccharide and its application | |
| CN110496179A (en) | A kind of method and application for rapidly and efficiently extracting antioxidant in Areca | |
| CN104306427A (en) | Rhodiola rosea extract and application thereof | |
| CN110882314B (en) | Eye lotion and preparation method thereof | |
| CN101947247B (en) | Method for preparing ginkgodipyidamolum injection | |
| CN1324040C (en) | Medicament for treating diabetes, diabetes complication, its preparation and novel use | |
| CN115490637B (en) | Preparation method and application of aporphine alkaloid compound | |
| CN108048504A (en) | A kind of extracting method of Moringa polysaccharide | |
| CN1884571A (en) | Process for extracting polysaccharide from lycoris plant | |
| CN101181486B (en) | Depression treating medicine and preparation method thereof | |
| CN1468860A (en) | Manyprickle acanthopanax general saponin extractive and its medicinal composition | |
| CN1891216A (en) | Use of catechin and its derivates for preparing medicine for preventing and treating neurodegenerative disease | |
| CN100343266C (en) | Picrorhiza total glycoside extract and its application in preparation of liver disease medicine and preparation method | |
| CN1785223A (en) | Medicine for treating muscular dystrophy and myasthenia gravis, and its prepn. method | |
| CN1762375A (en) | Erigeron breviscapus ketone ester and its injection preparation process | |
| CN104606180A (en) | Application of chlorogenic acid in preparation of medicines for treating epilepsy | |
| CN103800389A (en) | Hypoglycemic active ingredient in Sarcodon leucopus and preparation method and application thereof | |
| CN1233649C (en) | COmpound Bajisu A and its prepn and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: WANG FENG Free format text: FORMER OWNER: GUO DONGYU Effective date: 20130428 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 361012 XIAMEN, FUJIAN PROVINCE TO: 036900 SHUOZHOU, SHAANXI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130428 Address after: 036900 Shanxi province Shanyin County Youth Street Zhaohui District No. 2 hospital 5 ranked No. 5 Patentee after: Wang Feng Address before: Xiamen City, Fujian Province, 361012 East Road No. 226, Minmetals building 1717 Patentee before: Guo Dongyu |
|
| CX01 | Expiry of patent term |
Granted publication date: 20050323 |
|
| CX01 | Expiry of patent term |